Project Grant R37CA308018
Award Date 6/1/26
Completion Date 5/31/31
Dollars Obligated $636K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
San Francisco, CA 94143, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $375,150 to The Regents of the University of California, San Francisco under the Cancer Treatment Research program (CFDA 93.395) to fund a five-year research initiative (September 1, 2025 – August 31, 2030). The research addresses innate resistance mechanisms to KRAS inhibitors in cancer treatment, focusing on the role of the RhoA-ROCK-Myosin IIA cytoskeletal axis in promoting drug-tolerant persister...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Regents of the University of California, San Francisco a Project Grant of $675,009 under the Cancer Treatment Research program (CFDA 93.395) for the period August 1, 2026, through July 31, 2031. This award supports the development of covalent inhibitors targeting RAS Q61 mutations in cancer, building on prior breakthroughs in RAS G12C inhibitor drug discovery. The research addresses a critical gap in cancer...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $421,685 Project Grant to The Regents of the University of California, San Francisco under the Cancer Biology Research program (CFDA 93.396) for research activities spanning August 8, 2025 through July 31, 2027. This award funds a discovery-focused research initiative investigating functional immune niches within the tumor microenvironment (TME) that support effective cancer immunotherapy responses. The primary deliverable...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $661,721 to the University of California, San Diego under the Cancer Biology Research program (CFDA 93.396) beginning April 1, 2026, through March 31, 2031. This project grant supports systematic functional mapping and mechanistic interrogation of intrinsically disordered regions (IDRs) in oncogenic proteins across a five-year research period. The research deliverables include the development and application of novel...
- Federal Grant Award Summary The National Cancer Institute awarded The Institute For Cancer Research a $186,000 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on June 23, 2025, with a completion date of May 31, 2027. The award supports pilot and feasibility studies for NN-01-195, a novel tumor-targeted Aurora-A kinase (AURKA) inhibitor developed through a drug conjugate approach. The research involves preclinical evaluation of this chimeric compound, which fuses an...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $637,509 to the University of California, San Diego on May 11, 2026, under the Cancer Biology Research program (CFDA 93.396) to support fundamental research on integrated G protein circuitry mechanisms that drive cancer cell signaling autonomy. The research will be conducted through April 30, 2031, and focuses on investigating how the GA-interacting vesicle-associated protein (GIV) functions as a...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $648,177 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the University of California, Davis, effective April 1, 2026, with completion targeted for February 28, 2031. This award supports fundamental research aimed at developing mathematical models to characterize single-cell glycolytic rate variability using multiplexed live-cell measurement data. The research addresses a significant gap in...
- Federal Grant Award Summary The University of California, San Francisco (UCSF) received a Project Grant award of $700,338 from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), with an award date of May 11, 2026 and completion date of April 30, 2031. This five-year research project focuses on defining and overriding mechanisms of resistance to asciminib, the first allosteric tyrosine kinase inhibitor (TKI) approved for chronic myeloid leukemia (CML)...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $677,787 to The Regents of the University of California, San Francisco on August 26, 2025, under the Cancer Treatment Research program (CFDA 93.395). The award supports a five-year research initiative (through July 31, 2030) investigating AIRE-expressing tumor-associated macrophages (AIRE+ TAMs) as novel mediators of tumor immune evasion. The research aims to characterize the molecular and...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $663,340 Project Grant to the University of California, Berkeley under the Cancer Biology Research program (CFDA 93.396) to conduct fundamental research on regulatory T cell-mediated suppression of tumor elimination. The award, made on August 27, 2025 with completion targeted for July 31, 2030, will fund investigations into how the local ablation of intra-tumoral regulatory T cells (IT-Tregs) mobilizes natural killer...